Mackenzie Financial
VNDA icon

Mackenzie Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Mackenzie Financial’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,012
Closed -$240K – 1808
2024
Q4 		$240K Buy
+50,012
New +$240K ﹤0.01% 1481
2024
Q3 		– Sell
-10,937
Closed -$61.8K – 1681
2024
Q2 		$61.8K Sell
10,937
-4,027
-27% -$20.8K ﹤0.01% 1478
2024
Q1 		$61.5K Buy
14,964
+4,058
+37% +$16.2K ﹤0.01% 1470
2023
Q4 		$46K Buy
+10,906
New +$44K ﹤0.01% 1450

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial's VNDA Position: Q1 2025 in Review

Mackenzie Financial sold out of Vanda Pharmaceuticals (VNDA) in Q1 2025, closing a stake of 50,012 shares — an estimated $240K sold.

Mackenzie Financial first reported a position in VNDA in Q4 2023 and held it in 4 quarters. The position peaked at $240K in Q4 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q1 2025.

  • Mackenzie Financial reported no remaining Vanda Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Mackenzie Financial sold 50,012 Vanda Pharmaceuticals shares in Q1 2025, an estimated $240K.
  • Mackenzie Financial first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Mackenzie Financial's Vanda Pharmaceuticals position peaked at $240K in Q4 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2025.

Based on Mackenzie Financial's 13F filing for Q1 2025, filed 7 May 2025.